Sino Biopharmaceutical Ltd
HKEX:1177
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
HK |
|
Legal & General Group PLC
LSE:LGEN
|
UK |
|
TCL Electronics Holdings Ltd
HKEX:1070
|
CN |
|
Banco do Brasil SA
F:BZLA
|
BR |
|
R
|
Reliance Industries Ltd
LSE:RIGD
|
IN |
|
B
|
BirdDog Technology Ltd
ASX:BDT
|
AU |
|
A
|
Alamos Gold Inc
NYSE:AGI
|
CA |
|
PTC Therapeutics Inc
NASDAQ:PTCT
|
US |
|
G
|
GFT Technologies SE
XETRA:GFT
|
DE |
|
W
|
WashTec AG
XETRA:WSU
|
DE |
Wall Street
Price Targets
Price Targets Summary
Sino Biopharmaceutical Ltd
According to Wall Street analysts, the average 1-year price target for
Sino Biopharmaceutical Ltd
is 9.54 HKD
with a low forecast of 6.06 HKD and a high forecast of 12.81 HKD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is Sino Biopharmaceutical Ltd's stock price target?
Price Target
9.54
HKD
According to Wall Street analysts, the average 1-year price target for
Sino Biopharmaceutical Ltd
is 9.54 HKD
with a low forecast of 6.06 HKD and a high forecast of 12.81 HKD.
What is Sino Biopharmaceutical Ltd's Revenue forecast?
Projected CAGR
12%
For the last 14 years the
compound annual growth rate for
Sino Biopharmaceutical Ltd's revenue is
14%.
The projected
CAGR
for the next 3 years is
12%.
What is Sino Biopharmaceutical Ltd's Operating Income forecast?
Projected CAGR
18%
For the last 14 years the
compound annual growth rate for
Sino Biopharmaceutical Ltd's operating income is
16%.
The projected
CAGR
for the next 3 years is
18%.
What is Sino Biopharmaceutical Ltd's Net Income forecast?
Projected CAGR
56%
For the last 14 years the
compound annual growth rate for
Sino Biopharmaceutical Ltd's net income is
14%.
The projected
CAGR
for the next 2 years is
56%.
